Literature DB >> 10983715

Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).

M G Spillantini1, J C Van Swieten, M Goedert.   

Abstract

Tau is a microtubule-associated protein that binds to microtubules and promotes microtubule assembly. Six tau isoforms are produced in adult human brain by alternative mRNA splicing from a single gene. Inclusion of a 31-amino acid repeat encoded by exon 10 of the tau gene gives rise to the three isoforms with four microtubule-binding repeats each. The other three tau isoforms have three repeats each. Abundant neurofibrillary lesions made of tau protein constitute a defining neuropathological characteristic of Alzheimer's disease. Filamentous tau protein deposits are also the defining characteristic of other neurodegenerative diseases, many of which are frontotemporal dementias or movement disorders, such as Pick's disease, progressive supranuclear palsy and corticobasal degeneration. It is well established that the distribution of tau pathology correlates with the presence of symptoms of disease. However, until recently, there was no genetic evidence linking dysfunction of tau protein to neurodegeneration. This has now changed with the discovery of more than 15 mutations in the tau gene in "frontotemporal dementia and parkinsonism linked to chromosome 17" (FTDP-17). Clinically, this condition is characterised by profound personality changes, progressive dementia and extrapyramidal symptoms. Neuropathologically, all cases with tau mutations examined to date have shown an abundant filamentous tau pathology in brain cells. Pathological heterogeneity is determined to a large extent by the location of mutations in tau. Known mutations are either coding region or intronic mutations located close to the splice-donor site of the intron following exon 10. Most coding region mutations produce a reduced ability of tau to interact with microtubules, thus probably setting in motion the mechanisms that lead to the formation of tau filaments. Several of these mutations also promote sulphated glycosaminoglycan-induced assembly of tau into filaments. Intronic mutations and some coding region mutations produce increased splicing in of exon 10, resulting in an overexpression of four-repeat tau isoforms. Thus, a normal ratio of three-repeat to four-repeat tau isoforms is essential for preventing the development of tau pathology. Taken together, the new work has shown that dysfunction of tau protein causes neurodegeneration and dementia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10983715     DOI: 10.1007/pl00022972

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  23 in total

1.  PSF suppresses tau exon 10 inclusion by interacting with a stem-loop structure downstream of exon 10.

Authors:  Payal Ray; Amar Kar; Kazuo Fushimi; Necat Havlioglu; Xiaoping Chen; Jane Y Wu
Journal:  J Mol Neurosci       Date:  2011-09-01       Impact factor: 3.444

2.  Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.

Authors:  Michael DeTure; Li-Wen Ko; Colin Easson; Shu-Hui Yen
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

3.  Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau.

Authors:  Dara L Dickstein; Hannah Brautigam; Steven D Stockton; James Schmeidler; Patrick R Hof
Journal:  Brain Struct Funct       Date:  2010-03-07       Impact factor: 3.270

4.  Clinical, cognitive and anatomical evolution from nonfluent progressive aphasia to corticobasal syndrome: a case report.

Authors:  Maria Luisa Gorno-Tempini; Ryan C Murray; Katherine P Rankin; Michael W Weiner; Bruce L Miller
Journal:  Neurocase       Date:  2004-12       Impact factor: 0.881

5.  Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.

Authors:  Susana Boluda; Michiyo Iba; Bin Zhang; Kevin M Raible; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-12-24       Impact factor: 17.088

6.  Multiplex three-dimensional brain gene expression mapping in a mouse model of Parkinson's disease.

Authors:  Vanessa M Brown; Alex Ossadtchi; Arshad H Khan; Simon Yee; Goran Lacan; William P Melega; Simon R Cherry; Richard M Leahy; Desmond J Smith
Journal:  Genome Res       Date:  2002-06       Impact factor: 9.043

7.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Authors:  Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2007-06-20       Impact factor: 17.088

8.  Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation.

Authors:  Linn Hege Nilsen; Caroline Rae; Lars M Ittner; Jürgen Götz; Ursula Sonnewald
Journal:  J Cereb Blood Flow Metab       Date:  2013-01-23       Impact factor: 6.200

9.  Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild-type human tau.

Authors:  Tetsuya Kimura; Shunji Yamashita; Tetsuya Fukuda; Jun-Mi Park; Miyuki Murayama; Tatsuya Mizoroki; Yuji Yoshiike; Naruhiko Sahara; Akihiko Takashima
Journal:  EMBO J       Date:  2007-11-15       Impact factor: 11.598

10.  Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series.

Authors:  Barbara Borroni; Silvana Archetti; Antonella Alberici; Chiara Agosti; Massimo Gennarelli; Barbara Bigni; Cristian Bonvicini; Maria Ferrari; Giuseppe Bellelli; Daniela Galimberti; Elio Scarpini; Diego Di Lorenzo; Luigi Caimi; Carlo Caltagirone; Monica Di Luca; Alessandro Padovani
Journal:  Neurogenetics       Date:  2008-04-08       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.